Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937459 | 0.70 | CAPN1 (0.47) | CAPN1KDM4E | |
| SCHEMBL25937442 | 0.67 | CAPN1 (0.43) | CAPN1KDM4E | |
| SCHEMBL25937418 | 0.64 | CAPN1 (0.41) | CAPN1KDM4E | |
| SCHEMBL26303973 | 0.64 | CAPN1 (0.41) | CAPN1NPSR1 | |
| SCHEMBL26304015 | 0.59 | CAPN1 (0.37) | CAPN1 | |
| SCHEMBL11999052 | 0.55 | ADRA2C (0.48) | KDM4E | |
| SCHEMBL9665549 | 0.55 | ADRA2C (0.47) | CAPN1 | |
| SCHEMBL28231995 | 0.55 | ADRA2C (0.40) | CAPN1 | |
| SCHEMBL503017 | 0.55 | KDM4E (0.38) | CAPN1KDM4E | |
| SCHEMBL10553865 | 0.53 | ADRA2C (0.45) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958926-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO LTD (KR) | 2023-03-08 | — | — | EP | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2018-10-25 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| EP-2958926-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | Ewha University-Industry Collaboration Foundation (KR) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CAPN1 2475/4885TSHR 1755/4885NPSR1 1925/4885 |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CAPN1 2475/4885TSHR 1755/4885NPSR1 1925/4885 |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | PRDX1, PRDX2, PRDX5 | CAPN1 2475/4885TSHR 1755/4885NPSR1 1925/4885 |
| US-20180305377-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CAPN1 2475/4885TSHR 1755/4885NPSR1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.